AIM Immunotech Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by AIM Immunotech Inc. (AIM) on March 1, 2022, covering events occurring on that date and March 3, 2022. The company is incorporated in Delaware and trades on the NYSE American under the symbol "AIM."
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. This report focuses exclusively on corporate governance and executive compensation arrangements.
Material Changes
The primary material change reported is the appointment of a new Chief Financial Officer (CFO) and the transition of the outgoing CFO to a consulting role:
- New CFO Appointment: Robert Dickey IV was appointed as CFO, effective April 4, 2022. He will serve under a consulting agreement with Foresite Advisors, LLC, a company wholly-owned by Mr. Dickey.
- Outgoing CFO Transition: Ellen Lintal will step down as CFO on April 4, 2022, and transition to a consultant role providing accounting and financial services until December 31, 2022.
- Compensation: Mr. Dickey will be compensated at a rate of $375 per hour. The initial term of his agreement is one year.
Guidance, Outlook, and Risks
The filing contains no financial guidance or operational outlook. It includes a standard cautionary statement regarding forward-looking statements, noting that such statements involve risks and uncertainties and that the company does not undertake to update them. No specific risks or contingencies related to the executive changes were detailed beyond the standard termination clauses in the consulting agreements.
Key Facts for Investor Verification
- Verify the effective date of the CFO transition (April 4, 2022) and the interim management structure.
- Confirm the total potential cost of the new CFO arrangement based on the $375/hour rate and expected hours.
- Review the press release (Exhibit 99.1) for additional details on Mr. Dickey's strategic plans.
- Note that the filing does not disclose any financial performance data for the period.